ArticleMolecular medicine reports2019
Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.International journal of molecular sciences · 2025Review
- Effect of formononetin on progressive pulmonary pathologies: multitarget mechanisms and therapeutic prospects.Frontiers in pharmacology · 2025Review
- Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems.Frontiers in pharmacology · 2025Review
- Cell Death in Pulmonary Arterial Hypertension.International journal of medical sciences · 2024Review
- Beneficial effects of berberine against pulmonary complications of experimental pulmonary arterial hypertension in rats and some relevant mechanisms.Pulmonary circulation · 2023Article
- Article
- Notopterol Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat.Frontiers in cardiovascular medicine · 2022Article
- Formononetin Ameliorates Renal Dysfunction, Oxidative Stress, Inflammation, and Apoptosis and Upregulates Nrf2/HO-1 Signaling in a Rat Model of Gentamicin-Induced Nephrotoxicity.Frontiers in pharmacology · 2022Article
- TRIM32 inhibits the proliferation and migration of pulmonary artery smooth muscle cells through the inactivation of PI3K/Akt pathway in pulmonary arterial hypertension.Journal of bioenergetics and biomembranes · 2021Article
- Sodium Selenite Attenuates Balloon Injury-Induced and Monocrotaline-Induced Vascular Remodeling in Rats.Frontiers in pharmacology · 2021Article
- Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.Frontiers in pharmacology · 2021Review
- Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition.Frontiers in pharmacology · 2021Article
- Postpartum pulmonary circulation in pregnant rats with monocrotaline-induced pulmonary arterial hypertension.Journal of thoracic disease · 2020Article
- Perillyl alcohol, quercetin, and berberine combination therapy ameliorates experimental pulmonary arterial hypertension: Effects on the lung miR-204 expression, remodeling, and inflammatory factors.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a life‑threatening disease induced by the excessive proliferation and reduced apoptosis of pulmonary artery smooth muscle cells (PASMCs). Formononetin (FMN) is a natural isoflavone with numerous cardioprotective properties, which can inhibit the proliferation and induce the apoptosis of tumor cells; however, whether FMN has a therapeutic effect on PAH remains unclear. In the present study, PAH was induced in rats with monocrotaline (MCT, 60 mg/kg); rats were then administered FMN (10, 30 or 60 mg/kg/day). At the end of the experiment, hemodynamic changes, right ventricular hypertrophy and lung morphological characteristics were evaluated. α‑smooth muscle actin (α‑SMA), proliferating cell nuclear antigen (PCNA), and TUNEL were detected by immunohistochemical staining. The expression of PCNA, Bcl‑2‑associated X protein (Bax), Bcl‑2 and, cleaved caspase‑3, and activation of AKT and ERK were examined by western blot analysis. The results demonstrated that FMN significantly ameliorated the right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling induced by MCT. FMN also attenuated MCT‑induced increased expression of α‑SMA and PCNA. The ratio of Bax/Bcl‑2 and cleaved caspase‑3 expression increased in rat lung tissue in response to FMN treatment. Furthermore, reduced phosphorylation of AKT and ERK was also observed in FMN‑treated rats. Therefore, FMN may provide protection against MCT‑induced PAH by preventing pulmonary vascular remodeling, potentially by suppressing the PI3K/AKT and ERK pathways in rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.